Litigation Upate: Zantac Lawsuits Head to Southern Florida

by | Feb 10, 2020

On February 6th, the JPML released an order that will send over 140 lawsuits involving injuries caused by the heartburn medication Zantac to the Southern District of Florida. The judge assigned to preside over the consolidated cases, The Honorable Robin L. Rosenberg, will have the opportunity to oversee her first MDL.

Although other districts such as California, New Jersey and New York were considered, it was determined that Florida was the most convenient district given its location and resources.

The lawsuits allege that the defendants and manufacturers of Zantac (Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline LLC; Pfizer Inc.; Sanofi-Aventis U.S. LLC; Sanofi US Services Inc.; and Chattem, Inc.) were aware that the active ingredient in the medication, ranitidine, exposed plaintiffs to NDMA (a potent carcinogen known as N-nitrosodimethylamine). Research by an independent company showed that ranitidine molecules are inherently unstable and affect all drugs containing ranitidine, including both the name brand and generics, since they can drastically increase the level of NDMA in the body. Other manufacturers are also recalling other medicines containing ranitidine.

Read more about our Zantac Litigation Support Services or click on this link for information on Verus’ Mass Tort Services. To contact us, fill out this form or email us at and we will reply immediately.


About the Author


Share This